Hexylresorcinol
As of the edition of 20 October 2026, Hexylresorcinol is a small molecule: marketed, first approved in 1991 (CA).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1991
- Kind
- Small molecule
- Brand name
- Bradosol Lozenges Extra Strength
- First approved
- 31 December 1991 (CA)
- Approvals on record
- 7 in 1 region
- Holder of the most recent approval
- Reckitt Benckiser; 2 holders in all
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Reckitt Benckiser | Applicant | 2001 to now |